RHK RHON-KLINIKUM AG

EQS-News: RHÖN-KLINIKUM AG continues solid performance in the first nine months – outlook confirmed  

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Quarter Results/9 Month figures
RHÖN-KLINIKUM AG continues solid performance in the first nine months – outlook confirmed  

07.11.2024 / 08:59 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

Corporate News

Bad Neustadt a. d. Saale | 7 November 2024

 

RHÖN-KLINIKUM AG continues solid performance in the first nine months –
outlook confirmed  


RHÖN-KLINIKUM AG continues to report an increase in consolidated revenues and profit. In the first
nine months of financial year 2024, revenues were up by EUR 82.1 million to reach EUR 1,171.1 million
(9M 2023: EUR 1,089.0 million). Consolidated profit improved by 27.7% to EUR 30.4 million (9M 2023: EUR 23.8 million). At EUR 75.1 million, EBITDA was 2.3% above the level in prior year (9M 2023: EUR 73.4 million). From January to September 2023 a total of 688,787 patients were treated on an inpatient and outpatient basis in the hospitals and medical care centres, 3.6% more compared with the same period of the previous year (9M 2023: 664,594).

“We are taking various strategic measures enabling us to achieve a stable performance in this challenging market environment and are prepared for the hospital reform. In this regard, we are focusing on our strengths such as the specialisation of our facilities, the high level of treatment quality as well as the close collaboration within the Group’s network. Moreover, we are reinvesting our earnings in new staff and the infrastructure of our facilities to ensure our processes are effective and efficient”, said Prof. Dr. Tobias Kaltenbach, chairman of the Board of Management of RHÖN-KLINIKUM AG.

Outlook for 2024 confirmed

For the current financial year, RHÖN-KLINIKUM AG continues to expect revenues of EUR 1.6 billion within a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), a level of between EUR 110 million and EUR 120 million is expected.

The outlook is subject to considerable uncertainties in connection with the numerous global crises in the form of inflation and price increases and any regulatory measures impacting our remuneration structure in 2024.

The Quarterly Statement for Q3 2024 is published on the .

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 882,000 patients are treated at our five sites – RHÖN-KLINIKUM Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,200 persons. The innovative RHÖN Campus approach committed to cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are key elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA.  


Contact:

RHÖN-KLINIKUM AG | Head of Corporate Finance, Treasury, Investor Relations and Sustainability
Julian Schmitt | T. 50 |

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale



07.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail:
Internet: -klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 2024407

 
End of News EQS News Service

2024407  07.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2024407&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
07/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RHON-KLINIKUM AG

 PRESS RELEASE

EQS-News: RHÖN-KLINIKUM AG once again reports a successful financial y...

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Annual Report/Annual Results RHÖN-KLINIKUM AG once again reports a successful financial year – CEO Prof. Kaltenbach leaves the Board of Management as planned 27.03.2025 / 09:59 CET/CEST The issuer is solely responsible for the content of this announcement.   Corporate News Bad Neustadt a. d. Saale | 27 March 2025     RHÖN-KLINIKUM AG once again reports a successful financial year – CEO Prof. Kaltenbach leaves the Board of Management as planned RHÖN-KLINIKUM AG has met its financial targets as per forecast. R...

 PRESS RELEASE

EQS-News: RHÖN-KLINIKUM AG schließt Geschäftsjahr erneut erfolgreich a...

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Schlagwort(e): Jahresbericht/Jahresergebnis RHÖN-KLINIKUM AG schließt Geschäftsjahr erneut erfolgreich ab – Veränderungen im Vorstand / CEO Prof. Kaltenbach scheidet planmäßig aus dem Vorstand aus 27.03.2025 / 09:59 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.   Corporate News Bad Neustadt a. d. Saale | 27. März 2025 RHÖN-KLINIKUM AG schließt Geschäftsjahr erneut erfolgreich ab – Veränderungen im Vorstand / CEO Prof. Kaltenbach scheidet planmäßig aus dem Vorstand aus Die RHÖN-KLINIK...

 PRESS RELEASE

EQS-News: Befreiung nach § 37 Abs. 1 und Abs. 2 WpÜG i.V.m. § 9 Satz 1...

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Schlagwort(e): Sonstiges Befreiung nach § 37 Abs. 1 und Abs. 2 WpÜG i.V.m. § 9 Satz 1 Nr. 1 WpÜG-AngebVO von den Pflichten nach § 35 Abs. 1 Satz 1, § 35 Abs. 2 Satz 1 WpÜG in Bezug auf die RHÖN-KLINIKUM Aktiengesellschaft 25.11.2024 / 10:11 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. .awlist1_1732521480_896866 { list-style:none; counter-set:awlistcounter1 } .awlist1_1732521480_896866 li:before { content:'1.' counter(awlistcounter1); counter-increment:awlistcounter1 } .awlist2_1732...

 PRESS RELEASE

EQS-News: RHÖN-KLINIKUM AG continues solid performance in the first ni...

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Quarter Results/9 Month figures RHÖN-KLINIKUM AG continues solid performance in the first nine months – outlook confirmed   07.11.2024 / 08:59 CET/CEST The issuer is solely responsible for the content of this announcement.   Corporate News Bad Neustadt a. d. Saale | 7 November 2024   RHÖN-KLINIKUM AG continues solid performance in the first nine months –outlook confirmed   RHÖN-KLINIKUM AG continues to report an increase in consolidated revenues and profit. In the first nine months of financial year 2024, re...

 PRESS RELEASE

EQS-News: RHÖN-KLINIKUM AG setzt solide Entwicklung in den ersten neun...

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Schlagwort(e): Quartalsergebnis/9-Monatszahlen RHÖN-KLINIKUM AG setzt solide Entwicklung in den ersten neun Monaten fort – Ausblick bestätigt   07.11.2024 / 08:59 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.   Corporate News Bad Neustadt a. d. Saale | 7. November 2024   RHÖN-KLINIKUM AG setzt solide Entwicklung in den ersten neun Monaten fort – Ausblick bestätigt   Die RHÖN-KLINIKUM AG konnte weiterhin Umsatz und Konzerngewinn steigern. In den ersten neun Monaten des Geschäftsjahr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch